452 related articles for article (PubMed ID: 28155621)
1. Recent Approaches to Platinum(IV) Prodrugs: A Variety of Strategies for Enhanced Delivery and Efficacy.
Najjar A; Rajabi N; Karaman R
Curr Pharm Des; 2017; 23(16):2366-2376. PubMed ID: 28155621
[TBL] [Abstract][Full Text] [Related]
2. Platinum(iv) anticancer prodrugs - hypotheses and facts.
Gibson D
Dalton Trans; 2016 Aug; 45(33):12983-91. PubMed ID: 27214873
[TBL] [Abstract][Full Text] [Related]
3. Targeting drug delivery system for platinum(Ⅳ)-Based antitumor complexes.
Zhong Y; Jia C; Zhang X; Liao X; Yang B; Cong Y; Pu S; Gao C
Eur J Med Chem; 2020 May; 194():112229. PubMed ID: 32222677
[TBL] [Abstract][Full Text] [Related]
4. The Platin-X series: activation, targeting, and delivery.
Basu U; Banik B; Wen R; Pathak RK; Dhar S
Dalton Trans; 2016 Aug; 45(33):12992-3004. PubMed ID: 27493131
[TBL] [Abstract][Full Text] [Related]
5. Integrin-targeted delivery into cancer cells of a Pt(IV) pro-drug through conjugation to RGD-containing peptides.
Massaguer A; González-Cantó A; Escribano E; Barrabés S; Artigas G; Moreno V; Marchán V
Dalton Trans; 2015 Jan; 44(1):202-12. PubMed ID: 25369773
[TBL] [Abstract][Full Text] [Related]
6. Efficient co-delivery of a Pt(IV) prodrug and a p53 activator to enhance the anticancer activity of cisplatin.
Ma R; Wang Y; Yan L; Ma L; Wang Z; Chan HC; Chiu SK; Chen X; Zhu G
Chem Commun (Camb); 2015 May; 51(37):7859-62. PubMed ID: 25854514
[TBL] [Abstract][Full Text] [Related]
7. Photosensitive Pt(IV)-azide prodrug-loaded nanoparticles exhibit controlled drug release and enhanced efficacy in vivo.
Xiao H; Noble GT; Stefanick JF; Qi R; Kiziltepe T; Jing X; Bilgicer B
J Control Release; 2014 Jan; 173():11-7. PubMed ID: 24511610
[TBL] [Abstract][Full Text] [Related]
8. The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.
Johnstone TC; Suntharalingam K; Lippard SJ
Chem Rev; 2016 Mar; 116(5):3436-86. PubMed ID: 26865551
[TBL] [Abstract][Full Text] [Related]
9. Glycosylated Platinum(IV) Complexes as Substrates for Glucose Transporters (GLUTs) and Organic Cation Transporters (OCTs) Exhibited Cancer Targeting and Human Serum Albumin Binding Properties for Drug Delivery.
Ma J; Wang Q; Huang Z; Yang X; Nie Q; Hao W; Wang PG; Wang X
J Med Chem; 2017 Jul; 60(13):5736-5748. PubMed ID: 28603992
[TBL] [Abstract][Full Text] [Related]
10. Tailoring Platinum(IV) Amphiphiles for Self-Targeting All-in-One Assemblies as Precise Multimodal Theranostic Nanomedicine.
He S; Li C; Zhang Q; Ding J; Liang XJ; Chen X; Xiao H; Chen X; Zhou D; Huang Y
ACS Nano; 2018 Jul; 12(7):7272-7281. PubMed ID: 29906087
[TBL] [Abstract][Full Text] [Related]
11. Anticancer platinum (IV) prodrugs with novel modes of activity.
Chin CF; Wong DY; Jothibasu R; Ang WH
Curr Top Med Chem; 2011; 11(21):2602-12. PubMed ID: 22039869
[TBL] [Abstract][Full Text] [Related]
12. Fighting the resistance: rejuvenating anticancer platinum-based drugs.
O'Hare A
Nanomedicine (Lond); 2012 Jul; 7(7):947-8. PubMed ID: 23019670
[TBL] [Abstract][Full Text] [Related]
13. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
Ma ZY; Wang DB; Song XQ; Wu YG; Chen Q; Zhao CL; Li JY; Cheng SH; Xu JY
Eur J Med Chem; 2018 Sep; 157():1292-1299. PubMed ID: 30195239
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and Characterization of Nitric Oxide-Releasing Platinum(IV) Prodrug and Polymeric Micelle Triggered by Light.
Pramanick S; Kim J; Kim J; Saravanakumar G; Park D; Kim WJ
Bioconjug Chem; 2018 Apr; 29(4):885-897. PubMed ID: 29281788
[TBL] [Abstract][Full Text] [Related]
15. Targeting Energy Metabolism by a Platinum(IV) Prodrug as an Alternative Pathway for Cancer Suppression.
Jin S; Guo Y; Song D; Zhu Z; Zhang Z; Sun Y; Yang T; Guo Z; Wang X
Inorg Chem; 2019 May; 58(9):6507-6516. PubMed ID: 31013065
[TBL] [Abstract][Full Text] [Related]
16. Human Serum Albumin Conjugated Nanoparticles for pH and Redox-Responsive Delivery of a Prodrug of Cisplatin.
Shi H; Cheng Q; Yuan S; Ding X; Liu Y
Chemistry; 2015 Nov; 21(46):16547-54. PubMed ID: 26405808
[TBL] [Abstract][Full Text] [Related]
17. Advances in platinum chemotherapeutics.
Harper BW; Krause-Heuer AM; Grant MP; Manohar M; Garbutcheon-Singh KB; Aldrich-Wright JR
Chemistry; 2010 Jun; 16(24):7064-77. PubMed ID: 20533453
[TBL] [Abstract][Full Text] [Related]
18. Mono- and di-bromo platinum(IV) prodrugs via oxidative bromination: synthesis, characterization, and cytotoxicity.
Xu Z; Wang Z; Yiu SM; Zhu G
Dalton Trans; 2015 Dec; 44(46):19918-26. PubMed ID: 26514681
[TBL] [Abstract][Full Text] [Related]
19. Pt(IV) prodrugs containing microtubule inhibitors displayed potent antitumor activity and ability to overcome cisplatin resistance.
Li L; Huang X; Huang R; Gou S; Wang Z; Wang H
Eur J Med Chem; 2018 Aug; 156():666-679. PubMed ID: 30031977
[TBL] [Abstract][Full Text] [Related]
20. Targeted Drug Delivery System for Platinum-based Anticancer Drugs.
Gao C; Zhang Y; Chen J; Wang T; Qian Y; Yang B; Dong P; Zhang Y
Mini Rev Med Chem; 2016; 16(11):872-91. PubMed ID: 26586124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
